search
Back to results

Multiomics After Headache Provocation of People Who Are Unable to Have Headache

Primary Purpose

Headache, Healthy

Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Isosorbide Mononitrate 60 MG Extended Release Oral Tablet [Imdur]
Blood sample
Sponsored by
Danish Headache Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Headache

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Headache resistant and non-resistant male participants from the Danish Blood Donor Study.
  • Weight: 45 kg to 95 kg

Exclusion Criteria:

  • Daily consumption of any medication.
  • Consumption of any medication less than 12 hours prior to the study day.
  • Headache on the study day or 48 hours prior to the study day.
  • Amnestic or clinical signs of hypertension (systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg) or hypotension (systolic blood pressure <90 mmHg and/or diastolic blood pressure <50 mmHg).
  • Any severe cardiovascular disease, including cerebrovascular illness.
  • Amnestic or clinical signs of current mental illness.
  • Amnestic or clinical signs of current substance or drug abuse.
  • Amnestic or clinical signs of any illness the responsible doctor considers relevant for participation in the study.

Sites / Locations

  • Danish Headache Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Isosorbide mononitrate

Arm Description

Cases and controls both receive one tablet Imdur® 60 mg (isosorbide mononitrate) on the study day and have 3 sets of blood samples drown.

Outcomes

Primary Outcome Measures

Transcriptomic changes
Difference in RNA expression between cases and controls after headache provocation by Isosorbide Mononitrate.
Metabolomic changes
Difference in metabolites between cases and controls after headache provocation by Isosorbide Mononitrate.

Secondary Outcome Measures

Full Information

First Posted
January 3, 2020
Last Updated
March 24, 2021
Sponsor
Danish Headache Center
search

1. Study Identification

Unique Protocol Identification Number
NCT04218760
Brief Title
Multiomics After Headache Provocation of People Who Are Unable to Have Headache
Official Title
Pain Perception, Headache Provocation and Multiomics of People Who Are Unable to Have Headache
Study Type
Interventional

2. Study Status

Record Verification Date
March 2021
Overall Recruitment Status
Completed
Study Start Date
October 10, 2019 (Actual)
Primary Completion Date
March 12, 2020 (Actual)
Study Completion Date
March 12, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Danish Headache Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Headaches are extremely common illnesses with a combined lifetime prevalence of 90-99% in Europe. Despite this high prevalence, there are persons who have never, in their whole life, encountered a headache. The aim of the study is to identify factors that protect against headache by studying multiomics in people who never have had a headache (headache resistant) versus non-resistant controls. The investigators will measure multiomic changes (transcriptomics and metabolomics) after headache provocation with isosorbide mononitrate. 3 blood samples, two for RNA and one for metabolomics are taken right before administration of isosorbide mononitrate, 3 hours after administration of isosorbide mononitrate and again 5 hours after administration of isosorbide mononitrate. The investigators hope to contribute with novelty to the current understanding of headache pathophysiology and development of more efficient treatment of headache.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Headache, Healthy

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Case-control study.
Masking
None (Open Label)
Allocation
N/A
Enrollment
58 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Isosorbide mononitrate
Arm Type
Experimental
Arm Description
Cases and controls both receive one tablet Imdur® 60 mg (isosorbide mononitrate) on the study day and have 3 sets of blood samples drown.
Intervention Type
Drug
Intervention Name(s)
Isosorbide Mononitrate 60 MG Extended Release Oral Tablet [Imdur]
Intervention Description
1 tablet Isosorbide Mononitrate 60 mg administrated orally.
Intervention Type
Other
Intervention Name(s)
Blood sample
Intervention Description
3 blood samples from a periferal vein, two for RNA and one for metabolomics are taken right before administration of isosorbide mononitrate, 3 hours after administration of isosorbide mononitrate and again 5 hours after administration of isosorbide mononitrate.
Primary Outcome Measure Information:
Title
Transcriptomic changes
Description
Difference in RNA expression between cases and controls after headache provocation by Isosorbide Mononitrate.
Time Frame
5 hours
Title
Metabolomic changes
Description
Difference in metabolites between cases and controls after headache provocation by Isosorbide Mononitrate.
Time Frame
5 hours

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Headache resistant and non-resistant male participants from the Danish Blood Donor Study. Weight: 45 kg to 95 kg Exclusion Criteria: Daily consumption of any medication. Consumption of any medication less than 12 hours prior to the study day. Headache on the study day or 48 hours prior to the study day. Amnestic or clinical signs of hypertension (systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg) or hypotension (systolic blood pressure <90 mmHg and/or diastolic blood pressure <50 mmHg). Any severe cardiovascular disease, including cerebrovascular illness. Amnestic or clinical signs of current mental illness. Amnestic or clinical signs of current substance or drug abuse. Amnestic or clinical signs of any illness the responsible doctor considers relevant for participation in the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jes Olesen, Professor
Organizational Affiliation
Danish Headache Center
Official's Role
Study Director
Facility Information:
Facility Name
Danish Headache Center
City
Glostrup
State/Province
Region H
ZIP/Postal Code
2600
Country
Denmark

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Multiomics After Headache Provocation of People Who Are Unable to Have Headache

We'll reach out to this number within 24 hrs